JP2003516967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516967A5 JP2003516967A5 JP2001544683A JP2001544683A JP2003516967A5 JP 2003516967 A5 JP2003516967 A5 JP 2003516967A5 JP 2001544683 A JP2001544683 A JP 2001544683A JP 2001544683 A JP2001544683 A JP 2001544683A JP 2003516967 A5 JP2003516967 A5 JP 2003516967A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound
- formulation
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 13
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- 235000010290 biphenyl Nutrition 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 description 3
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- -1 cyano, hydroxy Chemical group 0.000 description 3
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- HJMZMZRCABDKKV-UHFFFAOYSA-N carbonocyanidic acid Chemical group OC(=O)C#N HJMZMZRCABDKKV-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17113999P | 1999-12-16 | 1999-12-16 | |
| US60/171,139 | 1999-12-16 | ||
| PCT/US2000/034504 WO2001044193A1 (en) | 1999-12-16 | 2000-12-18 | 1,3,4-substituted piperidine analogs and uses thereof in treating addictions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516967A JP2003516967A (ja) | 2003-05-20 |
| JP2003516967A5 true JP2003516967A5 (https=) | 2008-02-21 |
Family
ID=22622694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001544683A Pending JP2003516967A (ja) | 1999-12-16 | 2000-12-18 | １，３，４−置換ピペリジン類似体および嗜癖の治療におけるそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20020025967A1 (https=) |
| EP (1) | EP1248770A1 (https=) |
| JP (1) | JP2003516967A (https=) |
| CA (1) | CA2395075A1 (https=) |
| WO (1) | WO2001044193A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
| CN101163477A (zh) * | 2005-02-23 | 2008-04-16 | 普雷萨药品公司 | 多介质多巴胺转运抑制剂，以及其相关应用 |
| CN101163676A (zh) | 2005-02-23 | 2008-04-16 | 普雷萨药品公司 | 用于治疗运动障碍及其它cns适应症的多巴胺转运蛋白抑制剂 |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体 |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| CA2741731A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| EA201590053A1 (ru) | 2012-06-20 | 2015-08-31 | Новартис Аг | Модуляторы пути системы комплемента и их применение |
| WO2016019312A2 (en) * | 2014-07-31 | 2016-02-04 | Oregon Health & Science University | Vmat inhibitory compounds |
| RU2017118562A (ru) | 2014-10-31 | 2018-11-30 | Индивиор ЮКей Лимитед | Соединения-антагонисты дофаминового d3-рецептора |
| US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1058058B (de) * | 1954-02-27 | 1959-05-27 | Basf Ag | Verfahren zur Herstellung von Alkylpyridinen |
| GB850417A (en) * | 1957-05-31 | 1960-10-05 | Merck & Co Inc | Process for the preparation of 1-(p-nitrophenyl)-4-carboalkoxy-4-phenyl-piperidines |
| US4443451A (en) * | 1981-07-15 | 1984-04-17 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidin-5-one derivatives |
| DE3441927A1 (de) * | 1984-11-16 | 1986-05-28 | Basf Ag, 6700 Ludwigshafen | Am stickstoff substituierte 4-(p-tert.butyl-phenyl)-3-methyl-piperidine, dessen quartaere salze sowie deren anwendung als fungizide |
| US5620993A (en) * | 1995-06-07 | 1997-04-15 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| US6180648B1 (en) * | 1997-04-07 | 2001-01-30 | Biostream Therapeutics, Inc. | Analogs of cocaine |
| CA2346537A1 (en) * | 1998-10-07 | 2000-04-13 | Gian Luca Araldi | Monomeric and dimeric heterocycles, and therapeutic uses thereof |
-
2000
- 2000-12-18 US US09/739,184 patent/US20020025967A1/en not_active Abandoned
- 2000-12-18 EP EP00989325A patent/EP1248770A1/en not_active Withdrawn
- 2000-12-18 WO PCT/US2000/034504 patent/WO2001044193A1/en not_active Ceased
- 2000-12-18 JP JP2001544683A patent/JP2003516967A/ja active Pending
- 2000-12-18 CA CA002395075A patent/CA2395075A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003516967A5 (https=) | ||
| KR100236562B1 (ko) | 트라마돌 및 비-스테로이드성 소염제를 함유하는 조성물 | |
| JP2950597B2 (ja) | 硬膜外もしくは髄腔内局所投与用鎮痛剤 | |
| AU2005235422B2 (en) | New pharmaceutical compositions for the treatment of sexual disorders II | |
| DE60026855T2 (de) | Synergistische kombination von roflumilast und salmeterol | |
| CA2584524A1 (en) | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women | |
| RU2264401C3 (ru) | Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения и промежуточные вещества | |
| JP2006524660A5 (https=) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| RU2008146383A (ru) | ДИАЛКИЛФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МУСКАРИНОВЫХ РЕЦЕПТОРОВ | |
| WO2012072781A1 (en) | 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | |
| JP2005525364A5 (https=) | ||
| JP2003501469A5 (https=) | ||
| JPH02138214A (ja) | 不安を治療する方法 | |
| ATE410168T1 (de) | A1 adenosin-rezeptor-antagonisten | |
| JP2021512898A5 (https=) | ||
| US6403589B1 (en) | Method of treating pain with draflazine-analogues | |
| JP2005506369A (ja) | 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用 | |
| JP2005510468A5 (https=) | ||
| RU2002110106A (ru) | Новые производные пиримидин-2, 4,6-трионов, способ их получения и фармацевтические средства, содержащие эти соединения | |
| JP2001513532A (ja) | 痛みを処置するための方法 | |
| US5536749A (en) | Method for attenuation of sympathetic nervous system activity or onset of migraine by selectively metabolized beta-blocking agents | |
| CA2307028A1 (en) | Medicinal uses of phenylalkanols and derivatives | |
| WO1991018886A1 (en) | Compounds for the treatment of age-related memory impairment and other cognitive disorders | |
| CA2522888A1 (en) | Smooth muscle spasmolytic agents |